Rosen
Principal executive officer pay for Rosen, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Arcus Biosciences, Inc. (RCUS) FY2020–FY2025
Lagged peersTSR -65% vs peer group -41% over FY2020–FY2025
Paid for declineCAP $12,015,409→$17,732,855 while $100 invested went $257.03→$89.87 (FY2020–FY2025)
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2020 | $5.7M | $12.0M |
| FY2021 | $9.5M | $14.6M |
| FY2022 | $9.0M | -$2.1M |
| FY2023 | $10.1M | $7.5M |
| FY2024 | $7.3M | $4.8M |
| FY2025 | $9.7M | $17.7M |
The company's "$100 invested" index ran $257.03 at FY2020 → $89.87 by FY2025 — an annualized return of -19.0%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: -19.0%/yr at RCUS ( FY2020–FY2025). See the CEO track-record ranking for context.